About tg therapeutics inc. - TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
TGTX At a Glance
TG Therapeutics, Inc.
3020 Carrington Mill Boulevard
Morrisville, North Carolina 27560
| Phone | 1-212-554-4484 | Revenue | 329.00M | |
| Industry | Pharmaceuticals: Major | Net Income | 23.38M | |
| Sector | Health Technology | 2024 Sales Growth | 40.803% | |
| Fiscal Year-end | 12 / 2025 | Employees | 338 | |
| View SEC Filings |
TGTX Valuation
| P/E Current | 11.285 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 206.447 |
| Price to Sales Ratio | 14.669 |
| Price to Book Ratio | 21.095 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 112.981 |
| Enterprise Value to Sales | 14.495 |
| Total Debt to Enterprise Value | 0.053 |
TGTX Efficiency
| Revenue/Employee | 973,384.615 |
| Income Per Employee | 69,180.473 |
| Receivables Turnover | 2.547 |
| Total Asset Turnover | 0.725 |
TGTX Liquidity
| Current Ratio | 6.246 |
| Quick Ratio | 5.028 |
| Cash Ratio | 3.43 |
TGTX Profitability
| Gross Margin | 88.217 |
| Operating Margin | 12.744 |
| Pretax Margin | 7.779 |
| Net Margin | 7.107 |
| Return on Assets | 5.155 |
| Return on Equity | 12.215 |
| Return on Total Capital | 4.912 |
| Return on Invested Capital | 6.279 |
TGTX Capital Structure
| Total Debt to Total Equity | 114.101 |
| Total Debt to Total Capital | 53.293 |
| Total Debt to Total Assets | 43.92 |
| Long-Term Debt to Equity | 113.58 |
| Long-Term Debt to Total Capital | 53.05 |